Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrugs

Journal of Chemotherapy

Volumn 14, Issue 4, 2002, Pages 390-396

  Shibamoto, Yuta ^a   Mimasu, Y ^a   Tachi, Y ^a   Hatta, H ^a   Nishimoto, S ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

5 florouracil; 5 fluoro 2 deoxyuridine; 5 FU; Effector; FdUrd; Prodrug

Indexed keywords

FLOXURIDINE; FLUOROURACIL; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; MOUSE; NONHUMAN; TUMOR VOLUME;

EID: 0036693263     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.4.390     Document Type: Article

References (24)

1. Improved survival in stage III non-small-cell lung cancer: 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
2. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial
3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
4. 1-(5′-fluoro-6′-hydroxy-5′-6′-dihydrouracil- 5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions
5. A novel class of antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) that release 5-fluorouracil upon hypoxic irradiation
6. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′-oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs
7. In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation
8. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines
9. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid
10. In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines
11. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition
12. In vitro study on intrathecal use of 5-fluoro-2′-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors
13. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer
14. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas
15. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice
16. In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin
17. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2′-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model
18. 19F-NMR spectroscopy
19. Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system
20. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites
21. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas
22. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole
23. Cellular uptake of misonidazole and analogues with acidic and basic functons
24. Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use